CLINICAL TRIALS PROFILE FOR FLECTOR
✉ Email this page to a colleague
All Clinical Trials for FLECTOR
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT01054820 ↗ | Study to Assess the Effectiveness and Safety of FLECTOR Patch for Treatment of Acute Back Strain | Completed | Pfizer | Phase 4 | 2010-01-01 | Although approved for minor strains, sprains and contusions, FLECTOR Patch has not been studied extensively in the setting of acute back strain. This study is being conducted as an initial step in demonstrating the benefit of FLECTOR Patch specifically for back strain. In particular, this study is expected to provide information about the amount of improvement in back strain among subjects using the FLECTOR Patch, which may then be used to inform subsequent studies. |
| NCT02132247 ↗ | Safety Study of Flector Patch in Children With Minor Soft Tissue Injuries | Completed | IBSA Institut Biochimique SA | Phase 4 | 2014-05-01 | The primary purpose of this study is to determine whether Flector Patch is safe for use in children. The secondary purpose is to assess blood levels of diclofenac, the active ingredient in Flector Patch. |
| NCT02324270 ↗ | Safety and Efficacy of Generic Diclofenac Epolamine Acute Pain Due to Minor Ankle Sprain | Completed | Actavis Inc. | Phase 3 | 2014-05-01 | To demonstrate the therapeutic efficacy of a generic diclofenac epolamine patch against Flector patch in the treatment of pain in subjects with minor ankle sprain |
| NCT04585321 ↗ | Comparative Bioavailability and Local Tolerability of Two Topical Diclofenac Plasters Applied Once and Twice a Day | Completed | Fidia Farmaceutici s.p.a. | Phase 1 | 2017-11-28 | Study Objectives Primary To evaluate the average bioequivalence in healthy volunteers between medicinal product of Diclofenac Sodium 140mg Medicated Plaster EQI7 in comparison to the reference medicinal product Flector®, applied once and twice a day. Secondary To evaluate pharmacokinetic profile on Day 1, adhesivity, local tolerability and safety of medicinal product Diclofenac Sodium 140mg Medicated Plaster EQI7 in healthy volunteers in comparison to the reference medicinal product Flector®, applied once and twice a day. |
| NCT04976088 ↗ | Phase III Trial With Diclofenac Sodium Medicated Plaster in Patients With Impact Injuries of the Limbs | Completed | Fidia Farmaceutici s.p.a. | Phase 3 | 2018-05-25 | Phase III, multinational, multicentre, randomized, prospective, double blind, parallel groups, placebo-controlled study to evaluate the analgesic effects of Test Diclofenac Sodium 140mg medicated plaster, Reference DIEP 180 mg medicated plaster, Flector® and Placebo plaster in patients with painful and phlogistic disease due to acute traumatic events of the limbs. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for FLECTOR
Condition Name
Clinical Trial Locations for FLECTOR
Trials by Country
Clinical Trial Progress for FLECTOR
Clinical Trial Phase
Clinical Trial Sponsors for FLECTOR
Sponsor Name
